Does the media prefer INDV or CRVS?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Indivior. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Indivior's score of 0.42 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GRFS or CRVS?

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Grifols. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Grifols' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or CRVS?

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat CRISPR Therapeutics' score of 0.71 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRVS or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 9 mentions for Legend Biotech and 5 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Legend Biotech's score of 0.61 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Corvus Pharmaceuticals (CRVS) Competitors

$14.10 -0.80 (-5.37%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$14.25 +0.15 (+1.05%)

As of 04:02 AM Eastern

Compare

CRVS vs. INDV, GRFS, CRSP, LEGN, and KNSA

Should you buy Corvus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corvus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corvus Pharmaceuticals include Indivior (INDV), Grifols (GRFS), CRISPR Therapeutics (CRSP), Legend Biotech (LEGN), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Corvus Pharmaceuticals compare to Indivior?

Indivior (NASDAQ:INDV) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Indivior has a net margin of 19.44% compared to Corvus Pharmaceuticals' net margin of 0.00%. Corvus Pharmaceuticals' return on equity of -38.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

60.3% of Indivior shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Indivior has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.85	$210M	$1.95	20.06
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Indivior currently has a consensus target price of $40.29, suggesting a potential upside of 2.98%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 136.41%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Indivior. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Indivior's score of 0.42 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Grifols?

Grifols (NASDAQ:GRFS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Grifols presently has a consensus price target of $10.00, suggesting a potential upside of 31.41%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 136.41%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Grifols has a net margin of 5.54% compared to Corvus Pharmaceuticals' net margin of 0.00%. Grifols' return on equity of 6.21% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Grifols has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.05
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

In the previous week, Corvus Pharmaceuticals had 4 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 1 mentions for Grifols. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Grifols' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corvus Pharmaceuticals beats Grifols on 8 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

CRISPR Therapeutics currently has a consensus target price of $67.78, indicating a potential upside of 44.24%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 136.41%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

In the previous week, CRISPR Therapeutics had 6 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat CRISPR Therapeutics' score of 0.71 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Corvus Pharmaceuticals has lower revenue, but higher earnings than CRISPR Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,291.22	-$581.60M	-$6.22	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Summary

CRISPR Therapeutics beats Corvus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Legend Biotech?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Legend Biotech	$1.03B	4.19	-$296.80M	-$0.68	N/A

Corvus Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

In the previous week, Legend Biotech had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 9 mentions for Legend Biotech and 5 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Legend Biotech's score of 0.61 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 136.41%. Legend Biotech has a consensus target price of $57.00, suggesting a potential upside of 145.58%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.57

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Corvus Pharmaceuticals beats Legend Biotech on 8 of the 15 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Kiniksa Pharmaceuticals International has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Corvus Pharmaceuticals' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Kiniksa Pharmaceuticals International presently has a consensus target price of $65.14, indicating a potential upside of 4.10%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 136.41%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 2 mentions for Kiniksa Pharmaceuticals International. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Kiniksa Pharmaceuticals International's score of 0.82 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Corvus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.25B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-27.11	20.49	27.07	23.94
Price / Sales	N/A	300.32	515.45	90.30
Price / Cash	117.55	60.31	26.68	47.25
Price / Book	19.32	7.92	10.42	6.14
Net Income	-$15.28M	$23.81M	$3.60B	$331.74M
7 Day Performance	-5.81%	-1.09%	-1.26%	-1.81%
1 Month Performance	18.39%	2.56%	1.07%	-1.44%
1 Year Performance	216.85%	42.16%	23.61%	16.33%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	2.9622 of 5 stars	$14.10 -5.4%	$33.33 +136.4%	+231.0%	$1.25B	N/A	N/A	30
INDV Indivior	2.2569 of 5 stars	$40.23 +0.0%	$40.29 +0.1%	+144.3%	$4.90B	$1.24B	20.63	1,051
GRFS Grifols	4.02 of 5 stars	$7.02 -2.5%	$10.00 +42.5%	-23.4%	$4.90B	$8.51B	36.95	25,247	Upcoming Earnings Gap Up
CRSP CRISPR Therapeutics	3.4125 of 5 stars	$50.46 -0.3%	$67.78 +34.3%	-27.9%	$4.88B	$3.51M	N/A	460
LEGN Legend Biotech	3.2126 of 5 stars	$25.67 -0.3%	$57.00 +122.0%	-44.2%	$4.78B	$1.03B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. INDV, GRFS, CRSP, LEGN, and KNSA

How does Corvus Pharmaceuticals compare to Indivior?

Summary

How does Corvus Pharmaceuticals compare to Grifols?

Summary

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Legend Biotech?

Summary

How does Corvus Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. INDV, GRFS, CRSP, LEGN, and KNSA

How does Corvus Pharmaceuticals compare to Indivior?

Is INDV or CRVS more profitable?

Do institutionals & insiders believe in INDV or CRVS?

Which has stronger valuation & earnings, INDV or CRVS?

Which has more risk & volatility, INDV or CRVS?

Do analysts prefer INDV or CRVS?

Does the media prefer INDV or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Grifols?

Do analysts recommend GRFS or CRVS?

Is GRFS or CRVS more profitable?

Which has more volatility & risk, GRFS or CRVS?

Do institutionals & insiders hold more shares of GRFS or CRVS?

Which has better valuation & earnings, GRFS or CRVS?

Does the media prefer GRFS or CRVS?

Summary

How does Corvus Pharmaceuticals compare to CRISPR Therapeutics?

Do analysts prefer CRSP or CRVS?

Do insiders & institutionals believe in CRSP or CRVS?

Is CRSP or CRVS more profitable?

Does the media refer more to CRSP or CRVS?

Which has more volatility & risk, CRSP or CRVS?

Which has stronger earnings & valuation, CRSP or CRVS?

Summary

How does Corvus Pharmaceuticals compare to Legend Biotech?

Which has preferable earnings and valuation, CRVS or LEGN?

Which has more volatility & risk, CRVS or LEGN?

Does the media prefer CRVS or LEGN?

Do analysts recommend CRVS or LEGN?

Do institutionals & insiders have more ownership in CRVS or LEGN?

Is CRVS or LEGN more profitable?

Summary

How does Corvus Pharmaceuticals compare to Kiniksa Pharmaceuticals International?

Which has more volatility & risk, KNSA or CRVS?

Is KNSA or CRVS more profitable?

Which has preferable valuation and earnings, KNSA or CRVS?

Do analysts rate KNSA or CRVS?

Do insiders & institutionals believe in KNSA or CRVS?

Does the media prefer KNSA or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools